Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 96

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan for Patients with Advanced or Metastatic Non-small Cell Lung Cancer with Specific Genetic Changes

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Datopotamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Small cell lung cancer extensive stage

Not recruiting

Study of Ifinatamab Deruxtecan for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study of Atezolizumab and Chemotherapy for Patients with Non-Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion GECP

Squamous cell carcinoma of the hypopharynx+1

Not recruiting

Study on Preserving the Voice Box in Patients with Advanced Laryngeal or Hypopharyngeal Cancer Using Cisplatin, Fluorouracil, and Docetaxel Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Non-small cell lung cancer stage IV

Not recruiting

Study of BAT3306 or pembrolizumab with chemotherapy (carboplatin and pemetrexed) in patients with stage IV non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bio-Thera Solutions Ltd.

Small cell lung cancer extensive stage

Not recruiting

Study on the Effects of Defosbarasertib and Durvalumab for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Wheezing

Not recruiting

Study on the Effectiveness and Safety of OM-85 for Children Aged 6 Months to 5 Years with Recurrent Wheezing

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Colon cancer+5

Not recruiting

Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Not recruiting

Study of Sacituzumab Govitecan, Pembrolizumab, and a Platinum Drug Combination for Advanced Non-Small Cell Lung Cancer Patients Without Genomic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Hepatocellular carcinoma+14

Not recruiting

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Furmonertinib vs. Platinum-Based Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Arrivent Biopharma Inc.

Non-small cell lung cancer

Not recruiting

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.